ISSX Awards Program
The ISSX award program was established to recognize excellent scientific and service achievements in the scientific fields covered by the Society. We are proud to honor the following individuals for their achievements:
R.T. Williams Distinguished Scientific Achievement Award
C. Roland Wolf, Ph.D.
The R.T. Williams Distinguished Scientific Achievement Award is presented to an ISSX member from any region who has made substantial and seminal scientific contributions to the field over a sustained period and celebrates the individual's scientific accomplishment. This award recognizes the best in the field on international level. The 2019 recipient is C. Roland Wolf, OBE, FRSE, FMedSci, FRSA, FBTS, University of Dundee, Medical Research Institute.
Roland Wolf graduated from the University of Surrey in 1972 with a BSc Honors in Chemistry followed by a PhD in Biochemistry. Until recently, he held position of Research Director at the University of Dundee Medical Research Institute and was Honorary Director at the Cancer Research UK Molecular Pharmacology Unit. In addition, he was a founder and the Scientific Director of CXR Biosciences (now Concept Life Sciences), based in Dundee, UK. Currently, he is Professor of Molecular Pharmacology at Dundee University.
Professor Wolf’s primary research interests are understanding the pathways which determine the sensitivity of cells to drugs, environmental agents and chemical toxins, particularly molecular and genetic studies on how chemical agents interact with cells, how this influences their therapeutic and toxicological properties and how genetic polymorphisms in the genes involved relate to disease susceptibility, adverse drug pharmacology and toxicology. Specific current projects focus on preclinical drug development, the personalized treatment of cancer and the development of novel transgenic models to study drug pharmacology, disease etiology and the mechanisms that underlie the deleterious effects of environmental pollution.
He has published 533 papers in peer-reviewed scientific journals, cited over 28 thousand times and has an H index of 86. He has been a member of numerous national and international committees and advisory panels in academia, government and industry. He has also had many collaborations with the pharmaceutical industry. In 2001, Professor Wolf co-founded CXR Biosciences, with a major focus on applying new experimental models to accelerate drug development and reduce attrition when drugs enter man. Awarded an OBE in the 2010 New Year Honors List, Professor Wolf is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the Royal Society for the encouragement of Arts, Manufactures & Commerce and the British Toxicology Society. Professor Wolf is the recipient of the Gerhard Zbinden Award for contributions to the area of drug and chemical safety, the ISSX European Scientific Achievement Award (2005), the John Barnes award from the British Toxicology Society (2011) and the Scottish Enterprise Award for Leading Individual Contribution to Life Sciences in Scotland.
To recognize and celebrate Dr. Wolf’s substantial and sustained scientific contributions to the field of xenobiotic disposition spanning nearly five decades, he is awarded the 2019 R.T. Williams Distinguished Scientific Achievement Award.
The Frederick J. Di Carlo Distinguished Service Award
Charles Crespi, Ph.D.
The 2016 Frederick J. Di Carlo Distinguished Service Award is presented to an ISSX member from any region with an illustrious record of important service to the Society and its goals. The 2019 recipient is Charles Crespi.
Charles Crespi received his PhD in toxicology from the Massachusetts Institute of Technology. In the early 1980s Dr. Crespi and associates founded GENTEST Corporation, a company that became a leader in developing in vitro systems for the study of drug metabolism and safety. Areas of long-term research focus of Dr. Crespi include: the development of mammalian cells which are competent for the metabolism and transport of xenobiotics, the overexpression of xenobiotic metabolizing enzymes and transporters in various host systems and the development of novel applications of these systems to the discovery, development and safety assessment of new chemical entities.
A distinguished scientists and entrepreneur, Dr. Crespi has been a member of the International Society for the Study of Xenobiotics (ISSX) since the early 1990s. He served the Society in a variety of roles including poster awards committee, meeting organizing committees, as a member of the Finance Committee from 2006 – 2009 and as Treasurer for two years, 2010 - 2011. Dr. Crespi and his family generously endowed the R.T. Williams Distinguished Scientific Achievement Award.
For his active involvement, leadership, expertise, contributions, and commitment, ISSX is proud to honor Charles Crespi with the 2019 Frederick J. Di Carlo Distinguished Service Award.
Distinguished Accomplishments in Drug Discovery and Development
Raymond Evers, Ph.D.
The Distinguished Accomplishments in Drug Discovery and Development Award was created in 2018 to honor an individual or a team employed in an organization involved in drug discovery and/or drug development. The award is bestowed on the basis of a single high impact scientific accomplishment that dramatically changed practices in the ADME characterization of drugs or drug candidates or a sustained body of scientific work that shows high impact on the ADME characterization of drugs.
The inaugural recipient of this award is Raymond Evers, Director, Transporters and In Vitro Technologies, Drug Metabolism and Pharmacokinetics, Merck and Co. He is receiving this award for his significant and sustained contributions to the field of drug transporter science and enzymology that have had tremendous impact on his company’s portfolio and on the broader scientific and regulatory field.
Dr. Evers has had a tremendous impact with Merck and in the broader scientific community in the field of drug transporters and enzymology. His leadership and research have helped to improve the quality of the small molecule and peptide portfolio in discovery and development and have contributed to the approval of many registered drugs. Dr. Evers has continued to advance the discipline of drug transporters, drug-drug interactions, and DMPK in general, as evidenced by a strong and impactful record of publications and significant involvement in scientific societies.
For his high impact scientific accomplishments advancing the ADME characterization of drugs and drug candidates, Dr. Evers is awarded the ISSX Distinguished Accomplishments in Drug Discovery and Development Award.